Figure 6
From: Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats
Post-mortem biodistribution of Maraba viral genomes. Five healthy purpose-bred research cats were vaccinated intramuscularly with 1 × 1010 pfu of an E1/E3-deleted replication-deficient recombinant human serotype 5 adenovirus expressing the tumour-associated antigen human placenta specific 1 (hPLAC1) on day 0. On day 21 cats were boosted by intravenous infusion of 2.5 × 1011 pfu of a replication-competent Maraba virus expressing hPLAC1. On day 39 (i.e. 18 days post-boost), cats were euthanized for post-mortem quantification of Maraba viral genomes by quantitative RT-PCR. Tissues that were assessed included spleens from all cats, plus tissues with any abnormal lesions, which included the heart of one cat and the lung, liver and kidney of one other cat. Data values for each individual cat are shown.
